GPR55(G 蛋白偶联受体 55)是一种 G 蛋白偶联受体,在人类中由 GPR55 基因编码。GPR55 以及 GPR119 和 GPR18 被认为是新型大麻素受体。GPR55 由植物大麻素 9-THC 和大麻二酚以及内源性大麻素 anandamide、2-AG、noladin ether 在低纳摩尔范围内激活。最近的研究表明,溶血磷脂酰肌醇及其 2-花生四烯酰衍生物可能是 GPR55 的内源性配体,并且该受体似乎可能成为治疗炎症和疼痛的潜在靶点,就像其他大麻素受体一样。GPR55 的生理作用尚不清楚。GPR55 已被提议作为治疗糖尿病、帕金森病、神经性疼痛和癌症的新的潜在药物靶点。
GPR55 (G protein-coupled receptor 55) is a G protein-coupled receptor that in humans is encoded by the GPR55 gene. GPR55, along with GPR119 and GPR18, have been implicated as novel cannabinoid receptors. GPR55 is activated by the plant cannabinoids 9-THC and cannabidiol, and the endocannabinoids anandamide, 2-AG, noladin ether in the low nanomolar range. Recent research suggests that lysophosphatidylinositol and its 2-arachidonoyl derivative may be the endogenous ligands for GPR55, and the receptor appears likely to be a possible target for treatment of inflammation and pain as with the other cannabinoid receptors. The physiological role of GPR55 is unclear. GPR55 has been proposed as a new potential drug target for the treatment of diabetes, Parkinson’s disease, neuropathic pain, and cancer.
Tocrifluor 1117 (T1117) 是大麻素 CB1 受体拮抗剂 AM251 (MS-L64397) 的荧光形式,作为一种选择性 GPR55 配体,能很好地确定大麻素受体(包括活体组织中的 GPR55)的细胞位置,其激发光波长为 543 nm,发射光波长为 590 nm。
© 2026 MolStrong. 保留所有权利。粤ICP备2023004355号
可通过CAS号进行批量搜索,一行一个CAS号